Santos, M.Carvalho, S.Lima, L.Mota-Pereira, J.Pimentel, P.Correia, D.Maia, D.Gomes, S.Cruz, A.Medeiros, R.2023-01-192023-01-192022Santos, M., Carvalho, S., Lima, L., Mota-Pereira, J., Pimentel, P., Correia, D., Maia, D., Gomes, S., Cruz, A., & Medeiros, R. (2022). Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive Disorder. Abstracts of the 35th ECNP Congress 2022, 1, 100975. https://doi.org/10.1016/j.nsa.2022.100975http://hdl.handle.net/10400.22/21698Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. Several authors have been pointing out the role of the BDNF-TrkB signaling pathway, including the downstream kinases Akt and ERK, and the mTOR pathway in neuroplasticity [1-3]. Furthermore, the prediction of AD response phenotypes of depressed patients treated with AD drugs remains a challenge for clinicians. Although previous studies have suggested that genetic variants may play a key role in the mechanism of Treatment Resistance Depression and Relapse, attempts to identify risk polymorphisms within genes with putative interest in AD response, had a limited success.engjournal article10.1016/j.nsa.2022.100975